InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
As a leading genome editing company, Editas Medicine is focused on translating the...
As a leading genome editing company, Editas Med...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...
Neon Therapeutics is a clinical-stage immuno-on...
Intrommune Therapeutics is a New York City-based biopharmaceutical company develop...
Intrommune Therapeutics is a New York City-base...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...
Arena Pharmaceuticals is driven to deliver nove...
Join the National Investor Network and get the latest information with your interests in mind.